By: Amy Crowe, VP, Product Management- Claims, Cost, & Quality
In pharma and life sciences, most decisions about where to deploy field reps, MSLs, or run campaigns are anchored in claims data. Claims are the industry's default source of truth, and for good reason: they document what actually happened in a patient's care journey, with detail on diagnoses, procedures and prescription fills that few other datasets can match.
But claims do have one structural limitation that no amount of analysis can fix: they are retrospective. A medical or pharmacy claim typically arrives anywhere from 7 to more than 90 days after a patient is actually seen. By the time it surfaces, the patient has often already been diagnosed and received a prescription. The decisions a commercial team hoped to influence have already been made.
This delay has the greatest impact in the situations where commercial teams have the least room for error; that is, small, hard-to-find patient populations and competitive therapeutic areas where multiple brands compete for the same limited pool of eligible patients. In oncology and rare disease, there is an extremely narrow window for influence. If the data arrives weeks after the fact, the window has usually closed. Being second to know is functionally the same as not knowing at all.
This isn't theoretical. In an internal analysis, PurpleLab isolated oncology-related eligibility signals to flag providers verifying coverage tied to active oncology treatment, deliberately filtering out routine screening and non-treatment visits, to see, at a glance, which providers had oncology patients moving through the system, separate from the noise of routine screening, the kind of narrowing that gets sharper still once paired with claims history, as described below. For a therapeutic area where the addressable patient pool is small and the competitive field is crowded, that clarity is the difference between reaching a patient's care team while the decision is still open and finding out after a competitor already did.
So what is this signal, exactly, and why can you trust it?
Before most scheduled visits, a provider verifies the patient's insurance coverage with the payer. This exchange uses a standardized transaction set known as 270/271, the standard X12 EDI transaction set that providers use to verify a patient's insurance coverage with a payer before a visit or service. The 270 is the inquiry sent by the provider; the 271 is the response from the payer.
Importantly, it is carried out before care, not after. Therefore, an eligibility check is a key predictor that a diagnosis, specialist referral or prescription will soon be made. On average, it precedes any associated claim by roughly 4 to 7 days, and most matched claims land within 30 days of the check, with a median of about 22 days. In other words, while claims show a record of the patient journey, eligibility shows intent.
Because checks are tied to specific providers and payers, they reveal which organizations and prescribers are verifying coverage against which plans – a live view of where patient flow is heading and how the payer mix is distributed across a market. With patient tokens, this activity can also be linked back to claims data for a fuller longitudinal picture.
Eligibility check data is not a clean predictive feed. The raw transaction stream contains routine checks for coverage, and not every check corresponds to a real upcoming visit. The predictive signal only isolates cleanly after filtering for true pre-visit checks and removing any administrative back-and-forth.
Eligibility check data is not a replacement for claims. It does not contain prescription fills or a complete diagnosis and procedure history. It is an upstream complementary indicator. The teams that gain the most are those who already use claims and stack eligibility on top to close the timing gap, rather than swapping one for the other. Pairing the two is what makes the signal actionable: when an eligibility check is linked to a patient's existing claims history, teams can segment for patients who look likely to have a treatment decision coming soon, the same kind of narrowing that made the earlier oncology signal useful, rather than treating every check as an equally live signal.
Used well, the lead time changes what teams can do. Rather than reacting to a diagnosis after the fact, brand and field teams can spot trend breaks before they appear in claims, position resources, and/or set up campaigns accordingly.
Building on our existing real-world data foundation, PurpleLab now offers more than 4 billion standard eligibility transactions annually, with data feeds being received daily. PurpleLab also offers Eligibility Alerts as part of its Alerts product line. The product combines eligibility check activity with open medical and pharmacy claims to generate configurable daily or weekly alert feeds at the HCP or HCO level, with the filtering needed to surface pre-visit signals from operational noise. The data is updated daily, making it the fastest path to act on eligibility-driven insights before care occurs.
The takeaway: by the time a claim confirms what happened, the window to influence it has already closed. Eligibility data opens that window back up, days to weeks earlier, for teams willing to look upstream of claims.